Raynauds Disease – 2018 Pipeline Insights featuring Allergan, Apricus Biosciences, Covis Pharmaceuticals, and …

DUBLIN–(BUSINESS WIRE)–Jul 20, 2018–The “Raynauds Disease – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com‘s offering. This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Raynauds Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. The report assesses the active Raynauds Disease pipeline products by developmental stage, product type, molecule type, and administration route. Scope

The report provides a snapshot of the pipeline development for the Raynauds DiseaseThe report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Raynauds DiseaseThe report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Raynauds DiseaseThe report also covers the dormant and discontinued pipeline projects related to the Raynauds Disease

Allergan PlcApricus Biosciences IncCovis Pharmaceuticals IncHuman Stem Cells Institute

Key Topics Covered 1. Report Introduction 2. Raynauds Disease Overview 3. Pipeline Therapeutics 4. Comparative Analysis 5. Products in Clinical Stage 6. Products in Pre-Clinical and Discovery Stage 7. Therapeutic Assessment 8. Inactive Products For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4h3hmw/raynauds—disease?w=4

Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs


SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/20/2018 06:20 AM/DISC: 07/20/2018 06:20 AM

Copyright Business Wire 2018.

Source link

Leave a Reply

Your email address will not be published.